MarginsXMarginsX
Home › Markets › Health Care › DTIL

Precision BioSciences Inc. (DTIL)

DTIL trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$7.28
-3.77% on the day
Market cap
$277.6M
Micro cap
Revenue · 2025
$34.3M
-50.1% on 2024
Net income · 2025
-$45.7M
-133.4% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1357874/000162828026017019/0001628280-26-017019-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerDTIL on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO year2019
SEC CIK0001357874
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inDE

Financials · 2025

LineValue
Revenue$34.3M
Net income-$45.7M
Operating income-$52.1M
Net margin-133.4%
Operating margin-152.2%
Revenue growth-50.1%
Cash$110.8M
Total assets$154.4M
P/E (computed)Net income was not positive
P/S (computed)8.1×

Warning signs

Cash runway
18.9 months
$81.7M cash at September 30, 2026
Share count, 1 year
+110.7%
2025-10-29 to 2026-10-29 · +604.6% over 3 years
Going-concern doubt
No
10-Q filed November 3, 2026
Insider net buying, 12 months
-$384K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-03
Cash and burn$81.7M cash; operating cash flow -$12.9M a quarter.Report 2026-09-30
Shares outstanding27,935,719 (2026-10-29); 13,256,751 a year earlier; 118,935,191 three years earlier. 3y figure adjusted for split (1-for-30 overall).Cover page 2026-10-29
Reverse splits, 3 years1; latest 1-for-30 on 2024-02-14Source 2024-02-14
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the marketLatest 2026-11-06
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorDeloitte & Touche LLP, Raleigh, North Carolina, United StatesPCAOB Form AP 2026-03-24
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $63K, sold $447K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$0-$7.6M-$15.1M$81.7M$22.4M$45.0M10-Q 2026-11-03
Q2 2026
2026-06-30
$0-$32.7M-$13.4M$86.1M$22.4M$45.1M10-Q 2026-08-06
Q1 2026
2026-03-31
$10.8M-$18.4M-$11.9M$99.4M$22.4M$45.1M10-Q 2026-05-05
Q4 2025
2025-12-31
$34.2M$20.1M-$11.3M$110.8M$22.4M$34.3M10-K 2026-03-12
Q3 2025
2025-09-30
$13K-$21.8M-$15.3M$44.9M$22.4M$698K10-Q 2026-11-03
Q2 2025
2025-06-30
$18K-$23.5M-$20.3M$62.2M$22.4M$1.3M10-Q 2026-08-06
Q1 2025
2025-03-31
$29K-$20.6M-$19.1M$77.2M$22.3M$51.1M10-Q 2026-05-05
Q4 2024
2024-12-31
$638K-$17.7M-$18.7M$85.9M$22.3M$68.7M10-K 2026-03-12

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-11-06
Latest annual report10-K2026-03-12
Latest quarterly / interim10-Q2026-11-03
Latest current report8-K2026-11-09
Latest proxyDEFA14A2026-04-08

Source: SEC EDGAR submissions feed, 611 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-28.6%
1 month+24.0%
3 months+3.6%
Year to date+81.9%
1 year+29.3%
From 52-week high-28.6%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
ALLOAllogene Therapeutics Inc.$0.8070-3.78%$279.6M
AGENAgenus Inc.$6.29-6.54%$284.6M
SABSSAB Biotherapeutics Inc.$3.00+1.35%$270.3M
EDITEditas Medicine Inc.$1.87-13.82%$288.6M
XFORX4 Pharmaceuticals Inc.$2.83-9.29%$289.0M
LXEOLexeo Therapeutics Inc.$3.23+12.54%$265.0M
SCTXScribe Therapeutics Inc.$15.37-6.05%$291.1M
EIKNEikon Therapeutics Inc.$5.38-9.95%$291.8M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier